Epidermal growth factor-ferritin H-chain protein nanoparticles for tumor active targeting

Xu Li, Lihui Qiu, Pei Zhu, Xinyi Tao, Tadayuki Imanaka, Jing Zhao, Youguo Huang, Yaping Tu, Xuni Cao

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Human ferritin H-chain protein (FTH1)-based nanoparticles possess a precisely assembled nanometer-scale structure and high safety. However, their applications for imaging and drug delivery towards cancer cells remain limited due to a lack of target specificity. Epidermal growth factor receptor (EGFR) is overexpressed in many malignant tissues including breast cancer, and has been used as a therapeutic target for cancer treatment. Herein, a genetic method is shown to generate EGF-FTH1 chimeric proteins. EGF-FTH1 nanoparticles with EGF on the surface are then produced. The data demonstrate that EGF-FTH1 nanoparticles, with a small size (11.8 ± 1.8 nm), narrow size distribution, and high biosafety, can specifically bind to and then be taken up by breast cancer MCF-7 cells and MDA-MB-231 cells, but not normal breast epithelial MCF-10A cells. In contrast, binding and absorption of nontargeted ferritin-based nanoparticles to breast cancer cells are negligible. In vivo studies show that EGF-FTH1 nanoparticles are accumulated in breast tumors in a mouse xenograft model. Interestingly, the concentration of EGF-FTH1 nanoparticles in the tumor site is significantly reduced when mice are pretreated with an excess of free EGF. These results imply that EGF-EGFR interaction plays an important role in regulating the tumor retention of EGF-FTH1 nanoparticles.

Original languageEnglish
Pages (from-to)2505-2514
Number of pages10
JournalSmall
Volume8
Issue number16
DOIs
StatePublished - Aug 20 2012

Fingerprint

Apoferritins
Epidermal Growth Factor
Nanoparticles
Tumors
Proteins
Neoplasms
Breast Neoplasms
Epidermal Growth Factor Receptor
Cells
Oncology
MCF-7 Cells
Ferritins
Drug delivery
Heterografts
Breast
Tissue
Safety
Imaging techniques

All Science Journal Classification (ASJC) codes

  • Biomaterials
  • Engineering (miscellaneous)
  • Biotechnology
  • Medicine(all)

Cite this

Li, X., Qiu, L., Zhu, P., Tao, X., Imanaka, T., Zhao, J., ... Cao, X. (2012). Epidermal growth factor-ferritin H-chain protein nanoparticles for tumor active targeting. Small, 8(16), 2505-2514. https://doi.org/10.1002/smll.201200066

Epidermal growth factor-ferritin H-chain protein nanoparticles for tumor active targeting. / Li, Xu; Qiu, Lihui; Zhu, Pei; Tao, Xinyi; Imanaka, Tadayuki; Zhao, Jing; Huang, Youguo; Tu, Yaping; Cao, Xuni.

In: Small, Vol. 8, No. 16, 20.08.2012, p. 2505-2514.

Research output: Contribution to journalArticle

Li, X, Qiu, L, Zhu, P, Tao, X, Imanaka, T, Zhao, J, Huang, Y, Tu, Y & Cao, X 2012, 'Epidermal growth factor-ferritin H-chain protein nanoparticles for tumor active targeting', Small, vol. 8, no. 16, pp. 2505-2514. https://doi.org/10.1002/smll.201200066
Li, Xu ; Qiu, Lihui ; Zhu, Pei ; Tao, Xinyi ; Imanaka, Tadayuki ; Zhao, Jing ; Huang, Youguo ; Tu, Yaping ; Cao, Xuni. / Epidermal growth factor-ferritin H-chain protein nanoparticles for tumor active targeting. In: Small. 2012 ; Vol. 8, No. 16. pp. 2505-2514.
@article{a3d2ce5443554ad1a963feff4ed669aa,
title = "Epidermal growth factor-ferritin H-chain protein nanoparticles for tumor active targeting",
abstract = "Human ferritin H-chain protein (FTH1)-based nanoparticles possess a precisely assembled nanometer-scale structure and high safety. However, their applications for imaging and drug delivery towards cancer cells remain limited due to a lack of target specificity. Epidermal growth factor receptor (EGFR) is overexpressed in many malignant tissues including breast cancer, and has been used as a therapeutic target for cancer treatment. Herein, a genetic method is shown to generate EGF-FTH1 chimeric proteins. EGF-FTH1 nanoparticles with EGF on the surface are then produced. The data demonstrate that EGF-FTH1 nanoparticles, with a small size (11.8 ± 1.8 nm), narrow size distribution, and high biosafety, can specifically bind to and then be taken up by breast cancer MCF-7 cells and MDA-MB-231 cells, but not normal breast epithelial MCF-10A cells. In contrast, binding and absorption of nontargeted ferritin-based nanoparticles to breast cancer cells are negligible. In vivo studies show that EGF-FTH1 nanoparticles are accumulated in breast tumors in a mouse xenograft model. Interestingly, the concentration of EGF-FTH1 nanoparticles in the tumor site is significantly reduced when mice are pretreated with an excess of free EGF. These results imply that EGF-EGFR interaction plays an important role in regulating the tumor retention of EGF-FTH1 nanoparticles.",
author = "Xu Li and Lihui Qiu and Pei Zhu and Xinyi Tao and Tadayuki Imanaka and Jing Zhao and Youguo Huang and Yaping Tu and Xuni Cao",
year = "2012",
month = "8",
day = "20",
doi = "10.1002/smll.201200066",
language = "English",
volume = "8",
pages = "2505--2514",
journal = "Small",
issn = "1613-6810",
publisher = "Wiley-VCH Verlag",
number = "16",

}

TY - JOUR

T1 - Epidermal growth factor-ferritin H-chain protein nanoparticles for tumor active targeting

AU - Li, Xu

AU - Qiu, Lihui

AU - Zhu, Pei

AU - Tao, Xinyi

AU - Imanaka, Tadayuki

AU - Zhao, Jing

AU - Huang, Youguo

AU - Tu, Yaping

AU - Cao, Xuni

PY - 2012/8/20

Y1 - 2012/8/20

N2 - Human ferritin H-chain protein (FTH1)-based nanoparticles possess a precisely assembled nanometer-scale structure and high safety. However, their applications for imaging and drug delivery towards cancer cells remain limited due to a lack of target specificity. Epidermal growth factor receptor (EGFR) is overexpressed in many malignant tissues including breast cancer, and has been used as a therapeutic target for cancer treatment. Herein, a genetic method is shown to generate EGF-FTH1 chimeric proteins. EGF-FTH1 nanoparticles with EGF on the surface are then produced. The data demonstrate that EGF-FTH1 nanoparticles, with a small size (11.8 ± 1.8 nm), narrow size distribution, and high biosafety, can specifically bind to and then be taken up by breast cancer MCF-7 cells and MDA-MB-231 cells, but not normal breast epithelial MCF-10A cells. In contrast, binding and absorption of nontargeted ferritin-based nanoparticles to breast cancer cells are negligible. In vivo studies show that EGF-FTH1 nanoparticles are accumulated in breast tumors in a mouse xenograft model. Interestingly, the concentration of EGF-FTH1 nanoparticles in the tumor site is significantly reduced when mice are pretreated with an excess of free EGF. These results imply that EGF-EGFR interaction plays an important role in regulating the tumor retention of EGF-FTH1 nanoparticles.

AB - Human ferritin H-chain protein (FTH1)-based nanoparticles possess a precisely assembled nanometer-scale structure and high safety. However, their applications for imaging and drug delivery towards cancer cells remain limited due to a lack of target specificity. Epidermal growth factor receptor (EGFR) is overexpressed in many malignant tissues including breast cancer, and has been used as a therapeutic target for cancer treatment. Herein, a genetic method is shown to generate EGF-FTH1 chimeric proteins. EGF-FTH1 nanoparticles with EGF on the surface are then produced. The data demonstrate that EGF-FTH1 nanoparticles, with a small size (11.8 ± 1.8 nm), narrow size distribution, and high biosafety, can specifically bind to and then be taken up by breast cancer MCF-7 cells and MDA-MB-231 cells, but not normal breast epithelial MCF-10A cells. In contrast, binding and absorption of nontargeted ferritin-based nanoparticles to breast cancer cells are negligible. In vivo studies show that EGF-FTH1 nanoparticles are accumulated in breast tumors in a mouse xenograft model. Interestingly, the concentration of EGF-FTH1 nanoparticles in the tumor site is significantly reduced when mice are pretreated with an excess of free EGF. These results imply that EGF-EGFR interaction plays an important role in regulating the tumor retention of EGF-FTH1 nanoparticles.

UR - http://www.scopus.com/inward/record.url?scp=84864667428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864667428&partnerID=8YFLogxK

U2 - 10.1002/smll.201200066

DO - 10.1002/smll.201200066

M3 - Article

C2 - 22619186

AN - SCOPUS:84864667428

VL - 8

SP - 2505

EP - 2514

JO - Small

JF - Small

SN - 1613-6810

IS - 16

ER -